Join the 27th Annual International Lung Cancer Congress® HYBRID MEETING 👉 REGISTER FREE with code OncoAlert. buff.ly/YnjTuRM A high-impact update on lung cancer care, featuring the latest in immunotherapy, targeted therapy, ADCs, and multidisciplinary management. (HYBRID: OnLine & OnSite)

NEWS FROM INDUSTRY: OptiTROP-Lung06 Update in #LungCancer Source: PR Newswire Kelun-Biotech announced positive Phase III results from OptiTROP-Lung06 🫁 evaluating sacituzumab tirumotecan plus pembro as 1st-line therapy for PD-L1-negative, non-squamous #NSCLC . www.prnewswire.com/news-release...

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial www.thelancet.com/journals/lan...

The GUARD International Symposium 2026 to be held as a HYBRID meeting with in-person attendance and live streaming. It will bring together a multidisciplinary faculty to discuss advances in GU oncology. (English & Spanish) September 16–18, 2026 Madrid, Spain 🇪🇸 guardconsortium.org/actividad/gu...

FDA 🇺🇸granted traditional approval to selpercatinib on July 14, 2026 for adult and pediatric patients (age 2+) with locally advanced or metastatic RET 🧬fusion-positive solid tumors that progressed after prior treatment or lack satisfactory alternatives. fda.gov/drugs/resour...

Switching to camizestrant at ESR1 🧬 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6) www.thelancet.com/journals/lan...

Does the Use of PPI affect Immunotherapy?? The @OncoAlert 🚨 newsletter is Out GET IT HERE 👉 oncoalert.m-pages.com/nhMpwe/oncoa... Stay up to date with the most important practice-changing oncology research, expertly curated with concise take-home messages you can read in minutes.

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors www.nature.com/articles/s43... Researchers identified glycoprotein NMB (GPNMB) as a promising CAR T-cell target in solid tumors, with high and stable expression in alveolar soft-part sarcoma and translocation RCC

Dear Colleagues, Join @OncoAlert 🚨 LIVE in FLORENCE Italy Oct 9–10, for the 2nd International Multidisciplinary Consensus on Integrating Radiation Therapy with New Systemic Treatments (endorsed by ESTRO) ONLY 1️⃣ 5️⃣ 0️⃣ SPOTS for FREE Registration REGISTER HERE 👉 clinicaloncology.events

"It's about honesty, the basis is to be honest, even if its not nice for patients....We will cope with this" Eva Schumacher-Wulf Dear Friends, It is with a heavy heart that we learned this weekend that one of our longtime faculty members and dear friends has passed away.

Join the 27th Annual International Lung Cancer Congress® for a high-impact update on lung cancer care, featuring the latest in immunotherapy, targeted therapy, ADCs, and multidisciplinary management. (HYBRID: OnLine & OnSite) 👉 REGISTER FREE with code OncoAlert. buff.ly/YnjTuRM July 24-25

NEWS FROM INDUSTRY: ARTEMIS-008 🇨🇳 UPDATE in #SCLC #LungCancer 🫁 Source: GSK GSK's licensor Hansoh Pharma announced positive results from the phase III ARTEMIS-008 trial in Chinese patients with advanced or relapsed small-cell lung cancer. Risvutatug rezetecan (Ris-Rez) buff.ly/ZtAp2lC

FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer www.fda.gov/drugs/resour...

Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer www.thelancet.com/journals/lan...

This #WeekInOncology by @OncoAlert| GU Edition 🚨 Today, our GU Faculty Dr. Natalia Gandur 🇦🇷 reviews the LITESPARK-022 trial, led by OncoAlert Faculty member Dr. Toni K. Choueiri.🇺🇸 Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma NEJM, July 1, 2026 LINK👉 www.nejm.org/doi/full/10....

Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer www.nejm.org/doi/full/10.... In this phase 3 trial, 274 patients with completely resected ALK-positive stage IB–IIIB #NSCLC #LungCancer received ensartinib or placebo after adjuvant chemotherapy. Ensartinib 🧪 improved DFS

Two FREE ONLINE conferences for the OncoAlert community FREE HCP registration with code ONCOALERT. See you there! 👇 🎗️ Future of Breast Cancer East (25th Annual) 👉 www.gotoper.com/courses/inte... 🩸 MedicalCrossfire®: Hematologic 👉 registration.gotoper.com/mxh-26/home?...

EMA fast tracks review of a medicine for metastatic pancreatic cancer www.ema.europa.eu/en/news/ema-... The EMA’s CHMP has initiated a phased review of daraxonrasib, a potential treatment for previously treated metastatic #PancreaticCancer .

Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial www.nature.com/articles/s41...

📢 Join us at the 44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow 📅 November 11–13, 2026 (NY, NY🇺🇸 ) REGISTER 👉 buff.ly/b5A7hsf HYBRID MEETING (Online and In Person) 🚨 FREE🆓 REGISTRATION with Code: OncoAlert

Glucagon-Like Peptide-1 Receptor Agonists in Breast Cancer: Metabolic, Clinical, and Survivorship Implications ascopubs.org/doi/10.1200/...

Neoadjuvant Early Stereotactic Body Radiotherapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer www.advancesradonc.org/article/S245...

The OncoAlert Newsletter June 25- July 1, ,2026 REGISTER TO GET IT👉 buff.ly/X6N7qLU or buff.ly/4xd4naf

Antibody–drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer www.thebreastonline.com/article/S096...

Circulating Tumor DNA in Early Breast Cancer (Review) jamanetwork.com/journals/jam... Circulating tumor DNA (ctDNA) is a promising noninvasive biomarker for detecting minimal residual disease, monitoring treatment response, and identifying recurrence in early #BreastCancer .

Join our Collaborators at PER for the 10th Annual Live MedicalCrossfire®: Hematologic Malignancies. HCP's FREE REGISTRATION👉 buff.ly/Lg1r9DA (USE CODE: ONCOALERT ) THIS IS A HYBRID MEETING (IN PERSON & ONLINE) July 11-12, 2026 New York, NY or ONLINE

Join @gotoPER for Adopting New Treatment Strategies in Polycythemia Vera & Essential Thrombocythemia 🩸 REGISTER👉 buff.ly/UnUPkg3 HAPPENING VIRTUAL on July 8, 2026

EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway aacrjournals.org/cancerdiscov... KRASG12C inhibitors have shown limited and short-lived efficacy in lung adenocarcinoma due to acquired resistance

Dear Colleagues, Thank you for Following @OncoAlert 🚨 during #ESMOGI26 ! OncoAlert would like to thank our faculty for keeping worldwide up to date🌐 WE ARE ALL ONCOALERT !!

[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial www.thelancet.com/journals/lan...